One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1093/annonc/mdz394.039
Copy DOI Journal: Annals of Oncology |  Publication Date: Oct 1, 2019 |
 Citations: 57 |  License type: elsevier-specific: oa user license |
Affiliation: City Of Hope National Medical Center, Radboud University Nijmegen, Radboud University Nijmegen Medical Centre, University of Utah, Huntsman Cancer Institute, Centre Hospitalier de l’Université de Montréal, Peter MacCallum Cancer Centre, BC Cancer Agency, Carolina Urologic Research Center, AstraZeneca (United States), AstraZeneca (United Kingdom), Institute of Cancer Research, Northwestern University, Institut Gustave Roussy, University of Paris-Sud, Institut Polytechnique de Paris, Tulane University, Centre Hospitalier Universitaire de Besançon, Spanish National Cancer Research Centre, MSD (United States)LBA12_PR - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
